Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for "Methods of Administering 3,4-Diaminopyridine"
A Notice of Allowance is issued after the USPTO determines that the prosecution on the merits of a patent has been completed. The patent can then be granted from an application upon payment of the patent issue fee. Catalyst expects the patent to issue in the next few months. Once issued, the patent would be expected to expire no earlier than
“The receipt of this Notice of Allowance from the USPTO represents an important milestone in expanding our Firdapse® intellectual property portfolio and adds to Catalyst’s options for further developing the Firdapse® franchise,” said Dr.
Upon issuance of this patent, Catalyst will seek to list this patent in the
Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for myasthenia gravis.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) when the patent will officially be issued, (ii) when the patent, once officially issued, will expire, (iii) the scope of protection from competition provided by the patent, and (iv) those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2019 and its other filings with the
Brian KorbSolebury Trout (646) 378-2923 firstname.lastname@example.org Company Contact Patrick J. McEnany Catalyst PharmaceuticalsChief Executive Officer (305) 420-3200 email@example.com Media Contact David Schull Russo Partners(212) 845-4271 firstname.lastname@example.org
Source: Catalyst Pharmaceuticals, Inc.